Tvardi Therapeutics, Inc. (NASDAQ:TVRD) Stock Has Consensus Target Price of $9.40 According to Analysts

Shares of Tvardi Therapeutics, Inc. (NASDAQ:TVRD) have been assigned a consensus rating of “Moderate Buy” from the seven ratings firms that are presently covering the firm, Marketbeat.com reports. One investment analyst has rated the stock with a sell rating, five have issued a buy rating and one has assigned a strong buy rating to the company. The average 1-year price target among analysts that have issued ratings on the stock in the last year is $9.40.

A number of analysts have commented on TVRD shares. Wall Street Zen downgraded Tvardi Therapeutics from a “sell” rating to a “strong sell” rating in a report on Monday, October 12th. Piper Sandler raised Tvardi Therapeutics from a “neutral” rating to an “overweight” rating and set a $13.00 price objective for the company in a research report on Wednesday, July 8th. UBS Group raised Tvardi Therapeutics to an “outperform” rating and set a $10.00 price objective on the stock in a research note on Wednesday, July 8th. BTIG Research cut their target price on Tvardi Therapeutics to $5.00 and set a “buy” rating on the stock in a research report on Thursday, July 30th. Finally, Lucid Cap Mkts upgraded Tvardi Therapeutics to a “strong-buy” rating in a research report on Tuesday, September 8th.

Tvardi Therapeutics Stock Down 5.6%

TVRD opened at $1.01 on Tuesday. Tvardi Therapeutics has a twelve month low of $0.93 and a twelve month high of $6.65. The company has a fifty day moving average of $1.56 and a 200-day moving average of $2.48. The stock has a market cap of $13.47 million, a PE ratio of -0.36 and a beta of 0.38.

Tvardi Therapeutics (NASDAQ:TVRD) last announced its earnings results on Friday, August 14th. The company reported ($0.69) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.65) by ($0.04). Sell-side analysts anticipate that Tvardi Therapeutics will post -2.35 EPS for the current fiscal year.

Institutional Investors Weigh In On Tvardi Therapeutics

A number of hedge funds have recently added to or reduced their stakes in the business. GSA Capital Partners LLP acquired a new position in Tvardi Therapeutics in the second quarter valued at approximately $34,000. Susquehanna International Group LLP bought a new position in shares of Tvardi Therapeutics during the 2nd quarter worth approximately $63,000. Finally, BlackRock Inc. acquired a new stake in shares of Tvardi Therapeutics during the 2nd quarter worth approximately $181,000. 44.66% of the stock is currently owned by institutional investors.

Tvardi Therapeutics Company Profile

Tvardi Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing therapies for cancer and other serious diseases driven by abnormal STAT3 signaling. The company’s research is centered on inhibiting STAT3, a protein involved in tumor growth, immune evasion, inflammation and resistance to existing treatments.

Tvardi’s lead investigational product is TTI-101, an oral, small-molecule STAT3 inhibitor being evaluated in clinical studies for advanced solid tumors. The company is investigating the therapy both as a standalone treatment and in combination with other anticancer therapies, with the goal of addressing cancers in which STAT3 activity contributes to disease progression.

Tvardi Therapeutics is headquartered in Houston, Texas, and its development programs are focused on advancing targeted medicines through clinical testing.